Pharmaceutisch Weekblad

, Volume 2, Issue 1, pp 1669–1679 | Cite as

Recent advances in the classification of α- adrenoceptors

  • P. A. Van Zwieten
  • P. B. M. W. M. Timmermans
Review Articles


In contrast to the recent emphasis onβ-adrenoceptors, the adrenergic receptors of the α-type have been some-what neglected. However, the concept of pre- and post-synaptic α-adrenoceptors, which has been extended by the subdivision into α1- and α2-subtypes, has caused a revival of interest in this class of adrenoceptors. A clear distinction can now be made between pre- and post-synaptic α-adrenoceptors. This classification is based upon the anatomical localisation of the α-receptors in question. More recently, a subdivision into α1- and α2 subtypes has been generally recognised. This subdivision is based upon the drug specificities of these two distinct types of α-receptors. The present survey is dealing with the classification of α-adrenoceptors and their various subtypes. At present, a number of very selective agonists and antagonists of the subtypes of α-adrenoceptors mentioned above have become available. Their properties and possible therapeutic relevance are discussed in the present survey.


Public Health Internal Medicine Anatomical Localisation Distinct Type Clear Distinction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ahlquist, R. P. (1948)Am. J. Physiol. 153, 586–599.Google Scholar
  2. Andén, N. -E., H. Corrodi, K. Fuxe, B. Hökfelt, T. Hökfelt, C. Rydin andT. Svensson (1970)Life Sci. 9, 513–523.Google Scholar
  3. Andén, N. -E., M. Grabowska andU. Strömbom (1976)Naunyn-Schmiedebergs Arch. Pharmacol. 292, 43–52.Google Scholar
  4. Belleau, B. (1963)An analysis of drug-receptor interactions. Proc. Intern. Pharmacol. Meeting, ist, Stockholm 7. 75–95. Pergamon Press, Oxford;Ibidem (1967)Ann. N. Y. Acad. Sci. 139, 580–605.Google Scholar
  5. Berthelsen, S., andW. A. Pettinger (1977)Life Sci. 21, 595–606.Google Scholar
  6. Borowski, E., K. Starke, H. Ehrl andT. Endo (1977)Neuroscience 2, 285–296.Google Scholar
  7. Bunney, B. S., andG. K. Aghajanian (1975) In:Pre- and Postsynaptic Receptors (Usdin, E., andW. E. Bunney, Eds.). Marcel Dekker Inc., New York, p. 89–122.Google Scholar
  8. Drew, G. M. (1976)Eur. J. Pharmacol. 36, 313–320.Google Scholar
  9. Dubocovich, M. L., andS. Z. Langer (1976)J. Pharmacol. Exp. Therap. 198, 83–101.Google Scholar
  10. Farnebo, L. O., andB. Hamberger (1971)Acta Physiol. Scand. Suppl. 371, 35–44.Google Scholar
  11. Furchgott, R. F. (1967)Ann. N. Y. Acad. Sci. 139, 553–570.Google Scholar
  12. Gillespie, J. S., andT. C. Muir (1967)Brit. J. Pharmacol. 30, 78–86.Google Scholar
  13. Greenberg, D. A., D. C. U'prichard andS. H. Snyder (1976)Life Sci. 19, 69–76.Google Scholar
  14. Greengrass, P., andR. Bremner (1979)Eur. J. Pharmacol. 55, 323–326.Google Scholar
  15. Kobinger, W. (1978)Rev. Physiol. Biochem. Pharmacol. 81, 39–100.Google Scholar
  16. Kobinger, W., andL. Pichler (1976)Eur. J. Pharmacol. 40, 311–320;Ibidem (1977)Naunyn-Schmiedebergs Arch. Pharmacol. 300, 39–46;Ibidem (1980)Eur. J. Pharmacol. 65, 393–402.Google Scholar
  17. Lands, A. M., A. Arnold, J. P. Mcauliff, F. P. Luduena andT. G. Brown (1967)Nature (London) 214, 597–598.Google Scholar
  18. Langer, S. Z. (1974)Biochem. Pharmacol. 23, 1793–1800;Ibidem (1977)Brit. J. Pharmacol. 60, 481–497.Google Scholar
  19. Langer, S. Z., F. Pelayo andM. L. Dubocovich (1978) In:Perspectives in Nephrology and Hypertension (Schmitt, H., andP. Meyer, Eds.). John Wiley & Sons Ltd., New York, p. 327–337.Google Scholar
  20. Miach, P. J., J. P. Dausse, A. Cardot andP. Meyer (1980)Naunyn-Schmiedebergs Arch. Pharmacol. 312, 23–26.Google Scholar
  21. Moran, N. C., andM. E. Perkins (1958)J. Pharmacol. Exp. Therap. 124, 223–237.Google Scholar
  22. Mulder, A. H., J. Wemer andC. D. J. De Langen (1979) In:Presynaptic Receptors (Langer, S. Z., K. Starke andM. L. Dubocovich, Eds.). Pergamon Press, Oxford, p. 219–224.Google Scholar
  23. Peroutka, S. J., D. A. Greenberg, D. C. U'prichard andS. H. Snyder (1978)Mol. Pharmacol. 14, 403–412.Google Scholar
  24. Powell, C. E., andI. H. Slater (1958)J. Pharmacol. Exp. Therap. 122, 480–488.Google Scholar
  25. Rand, M. J., H. Majewski, M. W. Mcculloch andD. F. Story (1979) In:Presynaptic Receptors (Langer, S. Z., K. Starke andM. L. Dubocovich, Eds.). Pergamon Press, Oxford, p. 263–269.Google Scholar
  26. Sattler, H. W., andP. A. Van Zwieten (1967)Eur. J. Pharmacol. 2, 9–13.Google Scholar
  27. Schmitt, H. (1971)Actualités Pharmacol. 24, 93–131;Ibidem (1977) In:Antihypertensive Agents (Gross, F., Ed.). Springer-Verlag, Berlin p. 299–396.Google Scholar
  28. Schmitt, H., andH. Schmitt (1970)Eur. J. Pharmacol. 9, 7–13.Google Scholar
  29. Schmitt, H., H. Schmitt andS. Fénard (1971)Eur. J. Pharmacol. 14, 98–101;Ibidem (1973)Arzneimittel-Forsch. 23, 40–45.Google Scholar
  30. Starke, K. (1977)Rev. Physiol. Biochem. Pharmacol. 77, 1–124;Ibidem (1978) In:Recent Advances in the Pharmacology of Adrenoceptors (Szabadi, E., C. M.Brad-Shaw and P.Bevan, Eds.). Elsevier/North-Holland Biomedical Press, p. 173–180.Google Scholar
  31. Starke, K., andS. Z. Langer (1979) In:Presynaptic Receptors (Langer, S. Z., K. Starke andM. L. Dubocovich, Eds.). Pergamon Press, Oxford, p. 1–3.Google Scholar
  32. Starke, K., andH. Montel (1973)Naunyn-Schmiedebergs Arch. Pharmacol. 279, 53–60.Google Scholar
  33. Starke, K., H. Montel, W. Gayk andR. Merker (1974)Naunyn-Schmiedebergs Arch. Pharmacol. 285, 133–150.Google Scholar
  34. Starke, K., T. Endo andH. D. Taube (1975)Naunyn-Schmiedebergs Arch. Pharmacol. 2.91, 55–78.Google Scholar
  35. Starke, K., H. D. Taube andE. Borowski (1977)Biochem. Pharmacol. 26, 259–268.Google Scholar
  36. Taube, H. D., K. Starke andE. Borowski (1977)Naunyn-Schmiedebergs Arch. Pharmacol. 299, 123–141.Google Scholar
  37. Timmermans, P. B. M. W. M. (1980)Progr. Pharmacol., in press.Google Scholar
  38. Timmermans, P. B. M. W. M. (1981)Het Medisch Jaar 1981. Bohn, Scheltema & Holkema, Utrecht, in press.Google Scholar
  39. Timmermans, P. B. M. W. M., andP. A. Van Zwieten (1977)J. Med. Chem. 20, 1636–1644;Ibidem (1980a)Eur. J. Pharmacol. 63, 199–202;Ibidem (1980b)Naunyn-Schmiedebergs Arch. Pharmacol. 313, 17–20.Google Scholar
  40. Timmermans, P. B. M. W. M., H. Y. Kwa andP. A. Van Zwieten (1979)Naunyn-Schmiedebergs Arch. Pharmacol. 310, 189–193.Google Scholar
  41. Timmermans, P. B. M. W. M., F. Karamat Ali, S. P. Kossen andP. A. Van Zwieten (1980a)J. Pharm. Pharmacol. 32, 147.Google Scholar
  42. Timmermans, P. B. M. W. M., J. C. A. Van Meel andP. A. Van Zwieten (1980b)J. Autonomic Pharmacol., in press.Google Scholar
  43. Timmermans, P. B. M. W. M., A. M. C. Schoop, H. Y. Kwa andP. A. Van Zwieten (1980c)Eur. J. Pharmacol., in press.Google Scholar
  44. U'prichard, D. C., andS. H. Snyder (1977)J. Biol. Chem. 252, 6450–6463.Google Scholar
  45. U'prichard, D. C., D. A. Greenberg andS. H. Snyder (1977)Mol. Pharmacol. 13, 454–473.Google Scholar
  46. Weitzel, R., T. Tanaka andK. Starke (1979)Naunyn-Schmiedebergs Arch. Pharmacol. 308, 127–136.Google Scholar
  47. Westfall, T. C. (1977)Physiol. Rev. 57, 659–728.Google Scholar
  48. Wilffert, B., P. B. M. W. M. Timmermans andP. A. Van Zwieten (1979)Pharm. Weekblad 114, 245–255.Google Scholar
  49. Zwieten, P. A. Van (1975)Progress in Pharmacology 1, 1–63.Google Scholar
  50. Zwieten, P. A. Van, andP. B. M. W. M. Timmermans (1980a)Actualités Pharmacol. 32, 35–56;Ibidem (1980b)Pharmacology 21, 327–332.Google Scholar

Copyright information

© Bohn, Scheltema & Holkema 1980

Authors and Affiliations

  • P. A. Van Zwieten
    • 1
  • P. B. M. W. M. Timmermans
    • 1
  1. 1.Division of Pharmacotherapy, Department of PharmacyUniversity of AmsterdamTV AmsterdamThe Netherlands

Personalised recommendations